Review On AI Drug Discovery or Development
Year: 2026
Type: article
Abstract: Artificial Intelligence (AI) has emerged as a transformative technology in the pharmaceutical industry, particularly in medicinal chemistry and drug discovery. Traditional drug development is a complex, time-consuming, and costly process with a low success rate, often requiring extensive experimentation and significant financial investment. AI techniques, including Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), and Neural Networks (NN), offer innovative solutions to overcome these challenges by enabling efficient analysis of large datasets, accelerating target identification, optimizing lead compounds, and predicting drug efficacy and toxicity. AI-driven tools such as virtual screening, Quantitative Structure–Activity Relationship (QSAR) modeling, and predictive analytics have significantly improved the speed and accuracy of drug discovery processes. Furthermore, AI applications extend beyond drug discovery to pharmaceutical manufacturing, clinical trial design, market prediction, and product cost analysis, enhancing operational efficiency and decision-making. Generative AI technologies, including Generative Adversarial Networks (GANs), are also revolutionizing data generation, medical imaging, and personalized medicine. Despite its advantages, the adoption of AI in the pharmaceutical sector faces challenges such as data quality limitations, ethical concerns, interpretability issues, and regulatory uncertainties. Nevertheless, the integration of AI with traditional experimental methods holds great promise for improving drug development efficiency, reducing costs, and delivering safer and more effective therapies to patients.
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7213410680
